SBIR Phase I: Green Nanotechnology for Medicine: Scaling up the Synthesis of Novel Poly(ethylene glycol) Based Dendrimers for Targeted Drug Delivery Applications

SBIR 第一阶段：医药绿色纳米技术：扩大用于靶向药物输送应用的新型聚乙二醇树枝状聚合物的合成

• 批准号: 1214855
• 负责人: Kwang Su Seo
• 金额: $ 14.94万
• 依托单位: Arbomatrix, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1214855&HistoricalAwards=false
• 关键词: SBIR; Phase; Green; Nanotechnology; Medicine

This Small Business Innovation Research Phase I project is aimed at the demonstration of the feasibility of pilot scale production of a novel multivalent theranostic (combination of therapeutic and diagnostic) agent, capable of controlled presentation of multiple targeting ligands by a single nanosized macromolecule for chemotherapeutic applications. The proposing company was founded in 2011 with the objective of developing and marketing a range of biomedical products, based on technologies developed at the University of Akron (UA). The key outcome of the proposed research will be a novel poly(ethylene glycol) (PEG)-based dendrimer, produced by a "green" process using enzyme catalysis under solventless conditions. Specifically, a PEG-based dendrimer with 8 functional groups in the outer corona, available for the conjugation of targeting, imaging/diagnostic and therapeutic agents, will be produced at the two-gallon pilot scale for full characterization by the proposing team. The initial targeted market segment consists of researchers, research chemical suppliers, and companies and organizations doing research to develop new products for targeted drug delivery. The broader impact/commercial potential of this project is significant. Based on data from the National Cancer Institute, the number of Americans who are diagnosed with cancer will grow to 18.2 million. One specific benefit of this technology relates to its potential effects on breast cancer treatment. Breast cancer is the most frequently diagnosed cancer in both white and African-American women. One in eight American women develops breast cancer, and every three minutes a woman in the United States is diagnosed with breast cancer. Systemic treatment of cancer by chemotherapy has many side effects, requiring extended patient care. Targeted cancer treatment and diagnosis will have a major impact by minimizing the devastating side effects on the patient and his/her family. In the near term (3-5 years) we estimate a market potential on the order of $1-1.5 million, based on sales to researchers. In the longer term, the market size can potentially be in the hundreds of millions as the technology becomes embedded in specific products. Finally, the solventless "green" technology will have a positive effect on the environment.

这个小企业创新研究第一阶段项目的目的是证明一种新型多价治疗诊断剂（治疗和诊断的组合）的中试规模生产的可行性，能够通过单一的纳米大分子控制多个靶向配体的呈现，用于化疗应用。该公司成立于2011年，目标是开发和销售一系列基于阿克伦大学（UA）开发的技术的生物医学产品。 拟议的研究的主要成果将是一种新的聚（乙二醇）（PEG）为基础的树枝状大分子，生产的“绿色”过程中使用酶催化在无溶剂条件下。 具体而言，基于PEG的树枝状聚合物在外部冠中具有8个官能团，可用于靶向，成像/诊断和治疗剂的结合，将以两加仑的中试规模生产，由提议团队进行全面表征。 最初的目标市场部分包括研究人员，研究化学品供应商以及研究开发靶向药物输送新产品的公司和组织。该项目的更广泛影响/商业潜力是显著的。根据美国国家癌症研究所的数据，美国被诊断患有癌症的人数将增加到1820万。 这项技术的一个具体好处是它对乳腺癌治疗的潜在影响。 乳腺癌是白色和非洲裔美国妇女中最常诊断的癌症。八分之一的美国妇女患乳腺癌，每三分钟就有一名美国妇女被诊断出患有乳腺癌。 通过化学疗法对癌症进行系统治疗具有许多副作用，需要延长患者护理。有针对性的癌症治疗和诊断将通过最大限度地减少对患者及其家人的破坏性副作用而产生重大影响。 在短期内（3-5年），根据对研究人员的销售额，我们估计市场潜力在100 - 150万美元之间。 从长远来看，随着该技术嵌入到特定产品中，市场规模可能会达到数亿美元。 最后，无溶剂“绿色”技术将对环境产生积极影响。